Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578708 · ClinicalTrials.gov registry record · Phase 1
Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER
A Phase 1 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00578708 is a Phase 1 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 35 participants.
The verdict
NCT00578708, a Phase 1 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.
Interventions
- DEVICE AMPLATZER Membranous VSD Occluder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2003-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578708
The ClinicalTrials.gov registry entry for NCT00578708 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMPLATZER Membranous VSD Occluder is the first listed.
NCT00578708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00578708 about?
NCT00578708 is a clinical study titled "Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER". The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.
What is the current status of trial NCT00578708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2003-09. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00578708?
The interventions under investigation include: AMPLATZER Membranous VSD Occluder (DEVICE).
Who is sponsoring clinical trial NCT00578708?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.